

Charity registration number: 1164238

Action Kidney Cancer

Annual Report and Financial Statements

for the Year Ended 31 October 2022

Action Kidney Cancer

Contents (continued)

Reference and Administrative Details	1
Trustees' Report	2 to 5
Statement of Trustees' Responsibilities	6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10 to 17

Action Kidney Cancer

Reference and Administrative Details

Chairman	A Thomas
Trustees	A Thomas J Larkin J Pym A Fielding S Turajlic
Charity Registration Number	1164238
Principal Office	11th Floor 3 Piccadilly Manchester M1 3BN
Independent Examiner	Stockdale Accountants Ltd St Ingungur Offices Lanivet Bodmin Cornwall PL30 5HS

ACTION KIDNEY CANCER (Action Kidney Cancer is the working name of 'Kidney Cancer Support Network')

Trustees Report for the year ended 31st October 2022

The Trustees present their report together with the financial statement for the year ended 31st October 2022. In preparing this report, the Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "accounting and reporting by charities" issued in March 2005.

Registered charity number: 1164238 in England Wales, SC051330 in Scotland

Status: Charitable Incorporated Organisation (CIO) Incorporated 3 November 2015 England Wales

Status: Charitable Incorporated organisation (CIO) incorporated 7 October 2021 Scotland

Principal and registered address:

ACTION KIDNEY CANCER

Kidney Cancer Support Network,

11th Floor, 3 Piccadilly Place

Manchester M1 3BN

Trustees

I. Mr Andy Thomas – Chair

II. Professor James Larkin

III. Ms Debbie Victor (retired Nov 2021)

IV. Mr Jonathan Pym

V. Dr Samra Turajlic

VI. Ms. Alison Fielding

Structure, governance, and management

ACTION KIDNEY CANCER began its work as a voluntary support organisation in 2006. It was registered as a formal charitable incorporated organisation (CIO) on the 3 November 2015 and the charity is managed according to its governing documents dated 3 November 2015. The charity underwent a complete rebranding during in 2021 and is now known by its working name ACTION KIDNEY CANCER

Where there is a requirement for new Trustees, they will be identified and appointed by the current Trustees. The ACTION KIDNEY CANCER management team is responsible for the induction of any new Trustees, and this will involve a briefing about Trustee responsibilities, the governing document, and the adopted operating policies and procedures of the charity. All Trustees provide their services to the charity on a voluntary unpaid basis.

The Trustees delegate day-to-day responsibility for the running of the charity to the ACTION KIDNEY CANCER management team who are accountable to the Trustees and report to the Trustees throughout the year as required and at regular Trustee meetings.

The Trustees have a duty to identify and review all risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees regularly review the risks that the charity may face, and the Trustees will continue to monitor the risks associated with its activities and continue to be vigilant as to other risks that might be associated with a charity providing support services to people affected by kidney cancer.

The Trustees have agreed and adopted a series of operating policies to ensure the charity runs smoothly and complies with all charity commission requirements and legal responsibilities. The operating policies are reviewed every two years and are available by written request to the ACTION KIDNEY CANCER management team. Some policies are available via the ACTION KIDNEY CANCER website.

The Trustees declare as part of this annual return, that there are no serious incidents or other matters the Trustees should have reported to the Charity Commission.

Objectives and activities

To promote and protect the physical and mental health of patients with kidney cancer in the United Kingdom by:

1. The provision of information, support, education and practical advice to kidney cancer patients, their families, and their carers
2. To advance the education and awareness of all matters relating to kidney cancer with the general public
3. Promoting and supporting research projects into the causes, diagnosis, prevention, treatment, and cure of kidney cancer and disseminating the results of such research.

The Trustees meet a minimum of once a year, to discuss, agree and record charitable activities, strategy, funding priorities, and operating policies, including risk management. Project meetings are held throughout the year as required and/or as requested by the Trustees or management team.

Public benefit

The Trustees confirm that they have referred to the guidance provided by the charity commission's general guidance and advice on public benefit. In planning all activities including financial policies, the trustees confirm they have complied with the duty in section 17(5) of the 2011 Charities Act and the Trustees are satisfied that all charitable activities during the year are for the benefit of the public.

Achievements and performance

ACTION KIDNEY CANCER is a patient and carer led kidney cancer charity with a unique perspective and understanding of the needs of kidney cancer patients, carers, and their families. ACTION KIDNEY CANCER provides information, support, and advocacy to anyone affected by kidney cancer and seeks to educate and inform the public in all aspects of kidney cancer.

As we look back over 2021/22, at the forefront of everything was the aftermath of the COVID-19 pandemic. The pandemic is still having a significant impact on the NHS, our patient community, and the charity. We have continued to work hard, reaching out and supporting more kidney cancer patients and carers than ever before with updates and advice for patients about NHS waiting lists and delays and access to treatment and care services.

Post pandemic life is still difficult for patients, charities, and the NHS. Much is made of the NHS providing access to care and treatment in a timely manner but given the backlog of cancer cases, waiting times for diagnosis and surgery have increased, and delays for scan and test results lengthened. The psychological needs of kidney cancer patients and their families has increased exponentially, and our charity is still dealing with complex support cases as patients try to navigate the system to get timely appointments, scan results and 2nd opinions. Our charity is involved in complex cases of patients with co-morbidities trying to co-ordinate care and individual patients waiting months for routine clinic appointments. Especially difficult is the length of time some patients are waiting for results of scans, sometimes up to 2 months. This is unacceptable when scan results can be life changing, life is hanging in the balance every day until results are known. There are glaring inconsistencies across the Country; some results are reported on the same day while in other areas, results can take 8 weeks, these delays lead to even greater worry.

We are reliant on and thankful for the work of the ACTION KIDNEY CANCER team who have worked long hours to provide bespoke support and advice to individual patients and family members within our online community forum, via our freephone helpline telephone and via peer-to-peer email service and zoom/video links. In addition, we continue to provide kidney cancer news, research, updates and provide practical information about the COVID 19 vaccination programme which is still important for those patients who are clinically vulnerable.

Main Activities

- During the year and with agreement from the charity Trustees, we completed the rebranding of the charity to better reflect the breadth of the work the charity is now involved in. This included a new modern website, rebadged and complete with updated patient information and publicity materials. We now have provided an easily accessible modern website that is simple to use across all devices for patients, their families and healthcare professionals with a full range of downloadable resources.
- We have continued to provide an expert patient perspective at various online meetings, webinars and virtual conferences organised by the National Cancer Research Institute (NCRI), International Kidney Cancer Coalition (IKCC), National Health Service (NHS), pharmaceutical companies, National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC). In addition we have been proactive with other cancer advocacy organisations, such as
-

- Cancer52 – affiliate member,
 - One Cancer Voice (Cancer Research UK),
 - All.Can member
 - Coalition for Reducing Bureaucracy in Clinical Trials
 - Provided patient input to several important clinical trials, including REFINE, TRACERX, OPTIC and EquATOR clinical trial groups.
 - Independent Cancer Patient Voice (ICPV)
 - ABPI Patient Organisation Forum.
- This advocacy on behalf of the kidney cancer community is a vital part of our work and ACTION KIDNEY CANCER is recognised nationally and internationally as a genuine patient-led charity providing a strong patient focussed voice. We continue to campaign publicly for meaningful patient involvement in all aspects of research, diagnosis, care, treatment, survivorship, and wellbeing.
- We continue to work with the National Cancer Research Institute (www.ncri.org.uk) to help improve geographical spread, recruitment, and retention of patients into clinical trials around the UK and to further research towards a cure for kidney cancer. We are frequently involved in clinical trial design and data management committees. We are called on to review and/or help write clinical trial Patient Information Sheets and clinical trial protocols, and review patient videos for clinical trials. Two volunteer members of the ACTION KIDNEY CANCER sit as expert patient representatives on the NCRI Bladder and Renal Cancer Network which is a prestigious group of leading renal cancer clinicians and patient advocates.
- Provision of the only “peer to peer” kidney cancer helpline in the UK. We provide a friendly yet knowledgeable point of contact for patients and carers to discuss their concerns in an open, impartial, and non-judgemental way. Our aim is to provide patients with an individual and personal service, providing quality evidence-based information and personal advocacy.
- We have continued to invest time and funds in our unique kidney cancer clinical trials database on our website. The clinical trials database is a fully functional searchable database written in patient-friendly language and complemented with a full glossary and a range of patient educational resources, both written and video format. We offer support and work with individual patients to find specific clinical trials which patients can then talk to their hospital team about.
- Our unique private “peer to peer” online discussion forum has an active membership of over 1300 kidney cancer patients and carers. This 24/7 support service is managed and moderated by expert patients, caregivers, and advocates. This is a busy yet welcoming online forum that offers evidence-based information, shared patient experiences and patient, and carer support. Our discussion forum regularly records over 7000 comments & interactions every month covering all aspects of living with kidney cancer including sharing research news, treatment issues, side effects management, family relationships, work, survivorship, loss and beyond.
- ACTION KIDNEY CANCER is a founding member of the International Kidney Cancer Coalition (IKCC) and Rose Woodward is a volunteer Director of the IKCC Board. Through this affiliation with IKCC, ACTION KIDNEY CANCER works closely with other patient advocacy groups around the world to promote global awareness and better treatments for all kidney cancer patients. As a member of the IKCC Board, ACTION KIDNEY CANCER has been called upon to review materials for the kidney cancer community, take part in virtual international advisory boards and participate in online medical conferences and symposia to provide a genuine patient perspective.
- ACTION KIDNEY CANCER participated in the very successful International World Kidney Cancer Day that took place in June 2022. We led the UK campaign around a theme of “We need to talk about treatment options” raise awareness of clinical trials as a treatment option and to promote shared decision making and asking questions about access to treatments.
- We continue to produce our valuable professionally written quarterly ACTION KIDNEY CANCER kidney cancer newsletter updating our community of patient, carers, and healthcare professionals with the latest kidney cancer research and reviews, interviews, and patient perspectives into current news items.
- Over the year, we were able to play a leading role in several campaigns and took the opportunity to provide a strong patient voice into several nationally important pieces of work:
- Collaboration with Cancer52, One Cancer Voice and All.Can to make the health and care bill an Act of Parliament
 - Collaborated with Cancer52 and One Cancer Voice on the NHS England 10-year cancer plan.
 - Submitted comments on the following N I C E appraisals: lenvatinib plus pembrolizumab STA, nivolumab plus cabozantinib STA, adjuvant pembrolizumab STA.
 - Individual Charity submission to the N I C E consultation: N I C E methods and processes review
 - Submitted comments and attended the Scottish medicines Consortium PACE meeting and appraisal for adjuvant pembrolizumab STA.
 - Worked with Cancer52 on the NICE methods and processes review.

- Worked with All.Can on a campaign about the psychological well-being of cancer patients.
 - Charity submission to the Scottish government on the NHS Scotland 10-year cancer plan
 - Worked with Cancer52 on inequalities for rare and less common cancers.
 - Worked with the ABPI Patient Organisation Forum on the NICE methods and processes review.
 - Action Kidney Cancer also became members of the following organisations: Welsh Cancer Alliance, Scottish Cancer Coalition and Scottish Cross Party Group for cancer, Northern Ireland Cancer Coalition, we subsequently attended online meetings to ensure the kidney cancer patient perspective is heard.
- During the year, we launched three new fundraising projects: a virtual Lands End to John O'Groats route, resurrected the campaign previously run in Scotland of a Mad Hatters Tea Party and our Christmas "Gift a Heart" Campaign
 - We have continued our clear mission to provide evidence based, well researched, expert patient submissions to health technology appraisals (HTA) related to kidney cancer and the care of kidney cancer patients. We have provided expert patient statements at HTA committee meetings of NICE and the SMC Pace meetings.
 - As part of our international work, ACTION KIDNEY CANCER project managed and authored a comprehensive information book titled "Basics of Clinical trials". This booklet is published by IKCC (www.ikcc.org) and is freely available to patients and HCPs around the world for anyone wanting to understand more about kidney cancer clinical trials.
 - We have written & distributed patient-friendly highlights from the three main oncology conferences in Europe (ESMO) and North America (ASCO and ASCO GU).
 - Our main patient support project for the current financial year was a series of video interviews with expert clinicians and nurses designed to answer questions raised from within the community on the following topics. The expert videos involved clinicians and nurses with experience and knowledge of caring for patients with kidney cancer.
 - - Rehabilitation of kidney cancer patients following surgery.
 - Psychosocial support following a diagnosis of kidney cancer.
 - A healthy diet for kidney cancer patients.
 - Diagnostic scans and tests for kidney cancer.
 - Understanding the differences between palliative care and end of life care.

Financial review

Along with many other charities, the economic recession has affected our fundraising activities. People within the patient community have been hit especially hard by inflation coming so quickly after the problems caused by the pandemic. Once again, we been able capitalise on our excellent reputation for medical writing which, together with grants and donations have provided the income which allows us to provide our wide range of patient support services and to look at ways of increasing our reach.

During the financial year ending 31st October 2022, ACTION KIDNEY CANCER achieved an income of £137,075. The charity holds its funds in an ethical based community bank account with the Co-operative Bank. Our part-time Management Accountant works with our charity accountants Messrs. Stockdale Accountants with oversight from the Trustees. As part of good governance, the Action Kidney Cancer Trustees recommended a sum of funds of not less than 12 months core costs, be allocated to charity reserves in the next financial year to ensure the future sustainability of the charity is secured.

In 2022 we were able to access several industry grants which have enabled us to achieve the charity aims and objectives; we have supported more patients and families than ever before and answered more calls for support than ever before. The charity has maintained its focus on practical patient support, providing patients and families with up-to-date evidence-based information and we continue to raise awareness and increase understanding about kidney cancer at a local, national, and international level whenever the opportunity arises.

The Trustees and the management team would like to express their sincere thanks and appreciation to all the volunteers and supporters who have helped us to maintain much needed services to the community in such challenging times. Without the wonderful support from our community and volunteers, we would not be able to do what we do.

Signed Dated: 11 July 2023

Andy Thomas

Mr Andy Thomas – Chair of Trustees, ACTION KIDNEY CANCER

Action Kidney Cancer

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.


The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 11th July 2023 and signed on its behalf by:



A Thomas
Chairman and Trustee

Action Kidney Cancer

Independent Examiner's Report to the trustees of Action Kidney Cancer

I report to the trustees on my examination of the accounts of Action Kidney Cancer for the year ended 31 October 2022.

Responsibilities and basis of report

As the charity trustees of Action Kidney Cancer you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the Action Kidney Cancer's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement


I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of Action Kidney Cancer as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.


.....
Hayley Hall
MAAT

St Ingungger Offices
Lanivet
Bodmin
Cornwall
PL30 5HS

Date: 
.....

Action Kidney Cancer

Statement of Financial Activities for the Year Ended 31 October 2022

	Note	Unrestricted funds £	Total 2022 £
Income and Endowments from:			
Donations and legacies		106,704	106,704
Other income		30,371	30,371
Total income		<u>137,075</u>	<u>137,075</u>
Expenditure on:			
Charitable activities		<u>(87,212)</u>	<u>(87,212)</u>
Total expenditure		<u>(87,212)</u>	<u>(87,212)</u>
Net income		<u>49,863</u>	<u>49,863</u>
Net movement in funds		49,863	49,863
Reconciliation of funds			
Total funds brought forward		<u>204,846</u>	<u>204,846</u>
Total funds carried forward	11	<u>254,709</u>	<u>254,709</u>
		Unrestricted funds £	Total 2021 £
Income and Endowments from:			
Donations and legacies		107,698	107,698
Other income		40,505	40,505
Total income		<u>148,203</u>	<u>148,203</u>
Expenditure on:			
Charitable activities		<u>(90,875)</u>	<u>(90,875)</u>
Total expenditure		<u>(90,875)</u>	<u>(90,875)</u>
Net income		<u>57,328</u>	<u>57,328</u>
Net movement in funds		57,328	57,328
Reconciliation of funds			
Total funds brought forward		<u>147,517</u>	<u>147,517</u>
Total funds carried forward	11	<u>204,845</u>	<u>204,845</u>

All of the charity's activities derive from continuing operations during the above two periods.
The funds breakdown for 2021 is shown in note 11.

Action Kidney Cancer
(Registration number: 1164238)
Balance Sheet as at 31 October 2022

	Note	2022 £	2021 £
Fixed assets			
Tangible assets	7	243	486
Current assets			
Debtors	8	19,503	603
Cash at bank and in hand	9	<u>238,695</u>	<u>209,902</u>
		258,198	210,505
Creditors: Amounts falling due within one year	10	<u>(3,732)</u>	<u>(6,146)</u>
Net current assets		<u>254,466</u>	<u>204,359</u>
Net assets		<u>254,709</u>	<u>204,845</u>
Funds of the charity:			
Unrestricted income funds			
Unrestricted funds		<u>254,709</u>	<u>204,845</u>
Total funds	11	<u>254,709</u>	<u>204,845</u>

The financial statements on pages 8 to 17 were approved by the trustees, and authorised for issue on 11th July 2023 and signed on their behalf by:

Andy Thomas

A Thomas
Chairman and trustee

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022

1 Accounting policies

Statement of compliance

The financial statements have been prepared in accordance with the second edition of the Charities Statement of Recommended Practice issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Action Kidney Cancer meets the definition of a public benefit entity under FRS 102. The accounts (financial statements) have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022 (continued)

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets costing £100.00 or more are initially recorded at cost.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022 (continued)

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Statement of Financial Activities over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the charity has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022 (continued)

Debt instruments

Debt instruments which meet the following conditions are subsequently measured at amortised cost using the effective interest method:

(a) The contractual return to the holder is (i) a fixed amount; (ii) a positive fixed rate or a positive variable rate; or (iii) a combination of a positive or a negative fixed rate and a positive variable rate.

(b) The contract may provide for repayments of the principal or the return to the holder (but not both) to be linked to a single relevant observable index of general price inflation of the currency in which the debt instrument is denominated, provided such links are not leveraged.

(c) The contract may provide for a determinable variation of the return to the holder during the life of the instrument, provided that (i) the new rate satisfies condition (a) and the variation is not contingent on future events other than (1) a change of a contractual variable rate; (2) to protect the holder against credit deterioration of the issuer; (3) changes in levies applied by a central bank or arising from changes in relevant taxation or law; or (ii) the new rate is a market rate of interest and satisfies condition (a).

(d) There is no contractual provision that could, by its terms, result in the holder losing the principal amount or any interest attributable to the current period or prior periods.

(e) Contractual provisions that permit the issuer to prepay a debt instrument or permit the holder to put it back to the issuer before maturity are not contingent on future events, other than to protect the holder against the credit deterioration of the issuer or a change in control of the issuer, or to protect the holder or issuer against changes in levies applied by a central bank or arising from changes in relevant taxation or law.

(f) Contractual provisions may permit the extension of the term of the debt instrument, provided that the return to the holder and any other contractual provisions applicable during the extended term satisfy the conditions of paragraphs (a) to (c).

Debt instruments that are classified as payable or receivable within one year on initial recognition and which meet the above conditions are measured at the undiscounted amount of the cash or other consideration expected to be paid or received, net of impairment.

With the exception of some hedging instruments, other debt instruments not meeting these conditions are measured at fair value through profit or loss.

Commitments to make and receive loans which meet the conditions mentioned above are measured at cost (which may be nil) less impairment.

Investments

Investments in non-convertible preference shares and non-puttable ordinary or preference shares (where shares are publicly traded or their fair value is reliably measurable) are measured at fair value through profit or loss. Where fair value cannot be measured reliably, investments are measured at cost less impairment.

Investments in subsidiaries and associates are measured at cost less impairment. For investments in subsidiaries acquired for consideration including the issue of shares qualifying for merger relief, cost is measured by reference to the nominal value of the shares issued plus fair value of other consideration. Any premium is ignored.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022 (continued)

Derivative financial instruments

The charity uses derivative financial instruments to reduce exposure to foreign exchange risk and interest rate movements. The charity does not hold or issue derivative financial instruments for speculative purposes.

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. The resulting gain or loss is recognised in statement of financial activities immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in statement of financial activities depends on the nature of the hedge relationship.

Fair value measurement

The best evidence of fair value is a quoted price for an identical asset in an active market. When quoted prices are unavailable, the price of a recent transaction for an identical asset provides evidence of fair value as long as there has not been a significant change in economic circumstances or a significant lapse of time since the transaction took place. If the market is not active and recent transactions of an identical asset on their own are not a good estimate of fair value, the fair value is estimated by using a valuation technique.

2 Income from donations and legacies

	Unrestricted funds General £	Total funds £
Donations and legacies;		
Donations from individuals	26,704	26,704
Grants, including capital grants;		
Grants from other charities	80,000	80,000
Total for 2022	<u>106,704</u>	<u>106,704</u>
Total for 2021	<u>107,698</u>	<u>107,698</u>

3 Other income

	Unrestricted funds General £	Total funds £
Advocacy Fees	30,371	30,371
Total for 2022	<u>30,371</u>	<u>30,371</u>
Total for 2021	<u>40,505</u>	<u>40,505</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022 (continued)

4 Expenditure on charitable activities

	Note	Unrestricted funds General £	Total funds £
support of kidney cancer patients		86,969	86,969
Depreciation, amortisation and other similar costs		243	243
Total for 2022		<u>87,212</u>	<u>87,212</u>
Total for 2021		<u>90,875</u>	<u>90,875</u>

5 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

6 Taxation

The charity is a registered charity and is therefore exempt from taxation.

7 Tangible fixed assets

	Furniture and equipment £	Total £
Cost		
At 1 November 2021	<u>1,216</u>	<u>1,216</u>
At 31 October 2022	<u>1,216</u>	<u>1,216</u>
Depreciation		
At 1 November 2021	730	730
Charge for the year	<u>243</u>	<u>243</u>
At 31 October 2022	<u>973</u>	<u>973</u>
Net book value		
At 31 October 2022	<u>243</u>	<u>243</u>
At 31 October 2021	<u>486</u>	<u>486</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022 (continued)

8 Debtors

	2022 £	2021 £
Trade debtors	19,338	603
Prepayments	165	-
	<u>19,503</u>	<u>603</u>

9 Cash and cash equivalents

	2022 £	2021 £
Cash at bank	238,695	209,902

10 Creditors: amounts falling due within one year

	2022 £	2021 £
Trade creditors	3,330	6,046
Accruals	402	100
	<u>3,732</u>	<u>6,146</u>

11 Funds

	Balance at 1 November 2021 £	Incoming resources £	Resources expended £	Balance at 31 October 2022 £
Unrestricted				
General	<u>204,846</u>	<u>137,075</u>	<u>(87,212)</u>	<u>254,709</u>
	Balance at 1 November 2020 £	Incoming resources £	Resources expended £	Balance at 31 October 2021 £
Unrestricted				
General	<u>147,517</u>	<u>148,203</u>	<u>(90,875)</u>	<u>204,845</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2022 (continued)

12 Analysis of net assets between funds

	Unrestricted	Total funds
	General	2022
	£	£
Tangible fixed assets	243	243
Current assets	258,198	258,198
Current liabilities	<u>(3,732)</u>	<u>(3,732)</u>
Total net assets	<u>254,709</u>	<u>254,709</u>
	Unrestricted	Total funds
	General	2021
	£	£
Tangible fixed assets	486	486
Current assets	210,505	210,505
Current liabilities	<u>(6,146)</u>	<u>(6,146)</u>
Total net assets	<u>204,845</u>	<u>204,845</u>

Action Kidney Cancer

Detailed Statement of Financial Activities for the Year Ended 31 October 2022

	Total 2022 £	Total 2021 £
Income and Endowments from:		
Donations and legacies (analysed below)	106,704	107,698
Other income (analysed below)	<u>30,371</u>	<u>40,505</u>
Total income	<u>137,075</u>	<u>148,203</u>
Expenditure on:		
Charitable activities (analysed below)	<u>(87,212)</u>	<u>(90,875)</u>
Total expenditure	<u>(87,212)</u>	<u>(90,875)</u>
Net income	<u>49,863</u>	<u>57,328</u>
Net movement in funds	49,863	57,328
Reconciliation of funds		
Total funds brought forward	<u>204,846</u>	<u>147,517</u>
Total funds carried forward	<u><u>254,709</u></u>	<u><u>204,845</u></u>

Action Kidney Cancer

Detailed Statement of Financial Activities for the Year Ended 31 October 2022 (continued)

	Total 2022 £	Total 2021 £
<i>Donations and legacies</i>		
Appeals and donations	26,704	18,523
Grants - other agencies	80,000	89,175
	<u>106,704</u>	<u>107,698</u>
<i>Other income</i>		
Advocacy fees	30,371	40,505
	<u>30,371</u>	<u>40,505</u>
<i>Charitable activities</i>		
Rent	(495)	-
Insurance	(301)	(301)
Advocacy and medical relations	(25,439)	(19,205)
Telephone and fax	(201)	(294)
Communications	(10,380)	-
Office and administration	(6,441)	(15,925)
Website and maintenance	(7,914)	(30,548)
Patient Support	(16,260)	(23,046)
Sundry expenses	(4)	(35)
Conferences	(125)	-
Project management	(6,000)	-
Travel and subsistence	(161)	(29)
Marketing Material	(652)	-
Fundraising costs	(10,880)	-
Accountancy fees	(100)	(100)
Legal and professional fees	(1,025)	-
All Giving platform charges	(591)	(1,148)
Depreciation of office equipment	(243)	(243)
Office and administration	-	(1)
	<u>(87,212)</u>	<u>(90,875)</u>